Atlas FDA

THxID BRAF assay kit

FDA premarket approval P120014/S008 · decided 2018-06-27

Approval details

PMA number
P120014
Supplement
S008
Supplement type
Normal 180 Day Track
Supplement reason
Change Design/Components/Specifications/Material
Trade name
THxID BRAF assay kit
Generic name
Somatic gene mutation detection system
Applicant
bioMerieux, Inc.
Date received
2017-07-03
Decision date
2018-06-27
Days to decision
359 days
Decision code
APPR
Product code
OWD
Advisory committee
Pathology
Expedited review
No
Location
Hazelwood, MO
Statement
Approval for the THxID®-BRAF kit. It is an In Vitro Diagnostic device intended for the qualitative detection of the BRAF V600E and V600K mutations in DNA samples extracted from formalin-fixed paraffin-embedded (FFPE) human melanoma tissue. The THxID®-BRAF kit is a real-time PCR test on the ABI 7500 Fast Dx system and is intended to be used as an aid in selecting melanoma patients whose tumors carry: the BRAF V600E or V600K mutation for treatment with encorafenib [Braftovi] in combination with bi

Class III intelligence, same tools

PMAs share the API, exports and alerts with 510(k) data - watch an applicant and hear about every approval.

510(k) clearances by this applicant

RecordFirmDate
VITEK REVEAL GN AST Assay and VITEK REVEAL AST System (K260160)bioMerieux, Inc.2026-07-08
VITEK 2 AST-Streptococcus Inducible Clindamycin Resistance (K260282)bioMerieux, Inc.2026-04-15
VITEK 2 AST-Gram Negative Cefazolin (=<1-=>32 µg/mL) (K251579)bioMerieux, Inc.2025-08-21
VITEK COMPACT PRO (K234012)bioMerieux, Inc.2025-03-14
VITEK 2 AST-Yeast Voriconazole (<= 0.03125 - >= 4 µg/mL) (K232967)bioMerieux, Inc.2024-06-12
VITEK 2 AST-Yeast Anidulafungin (<= 0.015 - >= 8 µg/mL) (K232963)bioMerieux, Inc.2024-06-07
VIDAS TBI (GFAP, UCH-L1) (K240279)bioMerieux, Inc.2024-05-01
VITEK 2 AST-Gram Positive Lefamulin (<=0.03 - >=4 µg/mL) (K234000)bioMerieux, Inc.2024-03-11